News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors – ASCO
Collage of G Curigliano and Aditya Bardia
Oct 5, 2024, 09:20

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors – ASCO

ASCO shared a post on X:

“Experts Giuseppe Curigliano & Aditya Bardia discuss the results of the DESTINY-Breast06 trial, which showed significant PFS improvement with T-DXd in pts with HR+, HER2-low metastatic.”

DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive Metastatic Breast Cancer. How Do These Results Impact Practice for All Patients?

Authors: Giuseppe Curiglian and Aditya Bardia

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO

Source: ASCO/X

Aditya Bardia ASCO Breast Cancer cancer cancer awareness cancer care DESTINY-Breast06 fight against cancer Giuseppe Curigliano Global fight against cancer OncoDaily Oncology
Special Coverage
Insight
Oct 5, 2024, 09:20
DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO
Blog
Oct 5, 2024, 09:17
Mark Lawler: Economist Impact taking money from Big Tobacco while running heath conferences
Blog
Oct 5, 2024, 09:16
Jame Abraham: Shlomo Koyfman appointed as the Director of Precision Oncology Program at Cleveland Clinic
Blog
Oct 5, 2024, 09:15
Zainab Shinkafi-Bagudu: Fostering Global health equity through my work
Blog
Oct 5, 2024, 09:11
Owkin is entering a new partnership with AstraZeneca to develop a gBRCA pre-screening solution in breast cancer directly from digitised pathology slides
Insight
Oct 5, 2024, 09:09
Sunil Verma: AstraZeneca’s vision to redefine cancer care
Insight
Oct 5, 2024, 09:06
Michael Chuong: Incredible 5 days at the ASTRO annual meeting
Insight
Oct 5, 2024, 08:59
Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million
Insight
Oct 5, 2024, 08:53
Julia Shi: Great time at ASTRO24 with my fellow UTSW medical students
Insight
Oct 5, 2024, 08:51
ICCD Campaign highlights urgent global challenges in childhood cancer care
Insight
Oct 5, 2024, 08:48
Rille Pihlak: Investigating the balance between biomedical and humanistic competences in MedEd in oncology
Insight
Oct 5, 2024, 08:45
Extended lymphadenectomy to increase perioperative risks in Muscle-Invasive Bladder Cancer